Piramal Enterprises Limited
NSE: PEL BSE: PEL
NSE
1,124.20
8.80 (0.18%)
Prev Close
1124.2
Open Price
1129
Volume
2,148,582
Today Low / High
1108.5 / 1189
52 WK Low / High
848.25 / 1355.3
Range
1,068 - 1,180
BSE
1,124.60
2.80 (0.25%)
Prev Close
1121.8
Open Price
1122.8
Volume
67,905
Today Low / High
1110 / 1188
52 WK Low / High
849.9 / 1355.9
Range
1,068 - 1,181
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1124.2 (target range: 1,068 - 1,180), reflecting a change of 8.8 (0.18%). On the BSE, it is listed at 1124.6 (target range: 1,068 - 1,181), showing a change of 2.8 (0.2496%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Piramal Enterprises Limited Graph
Piramal Enterprises Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Piramal Enterprises Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,124.20, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,124.60 | 1,135.85 | 1,022.26 - 1,249.43 |
| 1,147.09 | 917.67 - 1,376.51 | ||
| 1,158.34 | 810.84 - 1,505.84 | ||
| Bearish Scenario | 1,124.60 | 1,113.35 | 1,002.02 - 1,224.69 |
| 1,102.11 | 881.69 - 1,322.53 | ||
| 1,090.86 | 763.60 - 1,418.12 |
Overview of Piramal Enterprises Limited
ISIN
INE140A01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
759,287
Market Cap
254,856,250,172
Last Dividend
11
Official Website
IPO Date
1996-01-02
DCF Diff
-894.93
DCF
2,028
Financial Ratios Every Investor Needs
Stock Dividend of PEL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-06-13 | June 13, 25 | 11 | 11 | 2025-06-13 | 2025-07-01 | |
| 2024-07-05 | July 05, 24 | 10 | 10 | 2024-07-05 | 2024-08-07 | |
| 2023-06-16 | June 16, 23 | 31 | 31 | 2023-06-16 | 2023-07-30 | |
| 2022-07-14 | July 14, 22 | 33 | 33 | 2022-07-15 | 2022-08-28 | |
| 2021-07-06 | July 06, 21 | 33 | 33 | 2021-07-07 | 2021-08-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8,916.13 Cr | 1,657.15 Cr | 7,258.98 Cr | 0.8141 | 0.00 Cr | 637.48 Cr | 7,032.87 Cr | 485.45 Cr | 21.55 | 6,140.46 Cr | 0.0544 |
| 2024-03-31 | 7,879.06 Cr | 1,406.56 Cr | 6,472.50 Cr | 0.8215 | 0.00 Cr | 689.80 Cr | 5,290.77 Cr | -1,683.53 Cr | -72.82 | 1,894.47 Cr | -0.2137 |
| 2023-03-31 | 8,031.79 Cr | 2,220.49 Cr | 5,811.30 Cr | 0.7235 | 0.00 Cr | 607.26 Cr | 3,794.49 Cr | 9,968.58 Cr | 417.68 | 8,684.95 Cr | 1.2411 |
| 2022-03-31 | 7,642.74 Cr | 1,901.88 Cr | 5,740.86 Cr | 0.7512 | 128.34 Cr | 307.93 Cr | 4,999.10 Cr | 1,923.11 Cr | 80.70 | 5,655.03 Cr | 0.2516 |
| 2021-03-31 | 12,770.76 Cr | 3,867.56 Cr | 8,903.20 Cr | 0.6972 | 79.31 Cr | 362.33 Cr | 6,928.52 Cr | 1,332.34 Cr | 56.19 | 8,105.18 Cr | 0.1043 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,991.84 Cr | 94,943.41 Cr | 67,847.47 Cr | 27,095.9400 Cr | 65,488.22 Cr | 59,212.33 Cr | 0.00 Cr | 521.55 Cr | 0.00 Cr | 178.40 Cr | 0.00 Cr | 23,508.1500 Cr |
| 2024-03-31 | 3,273.53 Cr | 82,605.00 Cr | 56,047.95 Cr | 26,557.0500 Cr | 53,585.93 Cr | 50,312.40 Cr | 0.00 Cr | 630.06 Cr | 0.00 Cr | 267.32 Cr | 10,333.76 Cr | 16,832.0100 Cr |
| 2023-03-31 | 3,729.00 Cr | 83,752.16 Cr | 52,693.08 Cr | 31,059.0800 Cr | 49,510.85 Cr | 45,781.85 Cr | 0.00 Cr | 556.45 Cr | -15,775.08 Cr | 140.43 Cr | 22,355.22 Cr | 18,742.0300 Cr |
| 2022-03-31 | 6,440.16 Cr | 99,872.91 Cr | 63,036.00 Cr | 35,489.1400 Cr | 55,702.96 Cr | 49,262.80 Cr | 1,533.01 Cr | 4,313.74 Cr | 5,208.31 Cr | 46.03 Cr | 17,529.27 Cr | 18,699.8800 Cr |
| 2021-03-31 | 5,719.01 Cr | 77,118.86 Cr | 41,979.90 Cr | 34,017.9600 Cr | 39,557.06 Cr | 33,838.05 Cr | 1,299.23 Cr | 3,327.10 Cr | 819.13 Cr | 35.49 Cr | 14,038.94 Cr | 13,347.2500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -8,090.8700 Cr | -1,854.4600 Cr | 11,663.6400 Cr | -8,364.6600 Cr | 1,718.3100 Cr | 4,991.8400 Cr | -273.7900 Cr | 485.4500 Cr | 11,979.4400 Cr | -225.1100 Cr | 0.0000 Cr |
| 2024-03-31 | 95.3600 Cr | -7,641.6900 Cr | 1,030.5700 Cr | -1,243.2600 Cr | -455.4700 Cr | 3,273.5300 Cr | -1,269.6900 Cr | -1,683.5300 Cr | 4,072.2400 Cr | -739.8600 Cr | 0.0000 Cr |
| 2023-03-31 | 1,359.3400 Cr | -351.2400 Cr | -3,324.5300 Cr | 1,156.7400 Cr | -2,555.0600 Cr | 3,729.0000 Cr | -202.6000 Cr | -2,464.3400 Cr | -2,499.4500 Cr | -787.5900 Cr | -2,127.9800 Cr |
| 2022-03-31 | 8,442.9900 Cr | -2,131.2700 Cr | -6,773.8500 Cr | 7,791.1700 Cr | 699.9800 Cr | 6,281.6300 Cr | -958.4200 Cr | 2,024.6800 Cr | -6,095.9300 Cr | -797.5900 Cr | -253.1800 Cr |
| 2021-03-31 | 3,664.5400 Cr | -2,772.2500 Cr | 2,071.5800 Cr | 3,069.3600 Cr | 2,970.0700 Cr | 5,581.6500 Cr | -595.1800 Cr | 3,058.4800 Cr | -596.5300 Cr | -315.7500 Cr | -231.2400 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2,525.46 Cr | 453.11 Cr | 2,072.35 Cr | 0.8206 | 2,023.26 Cr | 276.37 Cr | 12.22 | 1,849.84 Cr | 0.1094 |
| 2025-03-31 | 2,398.14 Cr | 405.21 Cr | 1,992.93 Cr | 0.8310 | 2,580.27 Cr | 102.44 Cr | 4.55 | 1,585.88 Cr | 0.0427 |
| 2024-12-31 | 2,298.30 Cr | 438.47 Cr | 1,859.83 Cr | 0.8092 | 1,605.95 Cr | 38.56 Cr | 1.71 | 1,508.85 Cr | 0.0168 |
| 2024-09-30 | 2,182.30 Cr | 425.43 Cr | 1,756.87 Cr | 0.8051 | 1,466.91 Cr | 162.97 Cr | 7.23 | 1,550.63 Cr | 0.0747 |
| 2024-06-30 | 2,037.39 Cr | 388.04 Cr | 1,649.35 Cr | 0.8095 | 1,379.74 Cr | 181.48 Cr | 8.08 | 1,495.10 Cr | 0.0891 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -27,095.94 Cr |
| 2025-03-31 | 4,991.84 Cr | 69.88 Cr | 9,761.48 Cr | 1,149.69 Cr | 0.00 Cr | 27,548.46 Cr | 521.55 Cr | 94,943.41 Cr | 67,847.47 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,929.94 Cr |
| 2024-09-30 | 1,978.82 Cr | 1,342.27 Cr | 3,321.09 Cr | 59.94 Cr | 0.00 Cr | 65,973.23 Cr | 563.69 Cr | 86,756.17 Cr | 59,826.23 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,557.05 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 276.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 102.44 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 38.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 162.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 181.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-12-30 | December 30, 19 | 128:125 |
| 2004-12-27 | December 27, 04 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,595.30 | ₹3,827,659,077,641.00 | ₹1,849,710.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,031.00 | ₹1,601,041,005,980.00 | ₹96,030.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,960.80 | ₹1,340,514,698,752.00 | ₹50,076.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,200.00 | ₹999,081,828,000.00 | ₹380,220.00 |
| Lupin Limited | LUPIN | ₹2,152.80 | ₹983,396,887,200.00 | ₹153,290.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹885.30 | ₹890,818,951,347.00 | ₹140,316.00 |
| Mankind Pharma Limited | MANKIND | ₹2,124.00 | ₹876,797,972,928.00 | ₹287,261.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,182.80 | ₹686,972,159,684.00 | ₹574,635.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,620.00 | ₹671,955,300,000.00 | ₹20,830.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,960.90 | ₹553,367,566,368.00 | ₹308,665.00 |
| Laurus Labs Limited | LAURUSLABS | ₹940.90 | ₹507,951,058,004.00 | ₹1,196,464.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,427.70 | ₹362,213,512,039.00 | ₹38,416.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,782.00 | ₹347,570,905,968.00 | ₹27,274.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,880.70 | ₹301,730,104,500.00 | ₹48,837.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,485.00 | ₹281,515,221,900.00 | ₹56,011.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,382.20 | ₹224,596,675,992.00 | ₹241,327.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,615.00 | ₹215,375,000,000.00 | ₹3,296.00 |
| Eris Lifesciences Limited | ERIS | ₹1,386.10 | ₹188,810,232,615.00 | ₹11,485.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹53,893.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹777.60 | ₹152,847,485,222.00 | ₹26,375.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹953.75 | ₹151,045,147,155.00 | ₹22,670.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹835.90 | ₹149,717,940,333.00 | ₹208,764.00 |
| Cohance Lifesciences Limited | COHANCE | ₹367.50 | ₹140,593,423,950.00 | ₹169,039.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,802.10 | ₹136,980,677,362.00 | ₹25,851.00 |
| Granules India Limited | GRANULES | ₹557.20 | ₹135,215,008,555.00 | ₹273,857.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹937.60 | ₹115,025,705,600.00 | ₹28,984.00 |
| Viyash Scientific Limited | VIYASH | ₹203.61 | ₹88,815,813,868.00 | ₹245,657.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,303.00 | ₹88,026,522,746.00 | ₹4,739.00 |
| Strides Pharma Science Limited | STAR | ₹877.00 | ₹80,835,470,178.00 | ₹379,638.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹756.05 | ₹68,533,886,629.00 | ₹69,500.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.00 | ₹68,283,517,868.00 | ₹92,422.00 |
| FDC Limited | FDC | ₹376.70 | ₹61,330,558,643.00 | ₹31,298.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹288.95 | ₹56,513,365,733.00 | ₹4,776,413.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹126.08 | ₹40,915,681,815.00 | ₹7,990,855.00 |
| Innova Captab Limited | INNOVACAP | ₹695.00 | ₹39,771,325,655.00 | ₹12,945.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.85 | ₹35,615,296,865.00 | ₹58,760.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹386.75 | ₹35,298,672,500.00 | ₹63,468.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹693.00 | ₹35,148,339,765.00 | ₹14,366.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,007.90 | ₹33,208,688,219.00 | ₹3,827.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹303.90 | ₹30,475,853,573.00 | ₹29,080.00 |
| Suven Life Sciences Limited | SUVEN | ₹132.81 | ₹30,210,821,940.00 | ₹346,948.00 |
Key Executives
Executive Chairman
Ajay Gopikisan Piramal
Gender: male
Year Born: 1955
Executive Director
Anand Ajay Piramal
Gender: male
Year Born: 1984
Group General Counsel
Anand Vardhan
Gender: male
Year Born:
BR Head & Company Secretary
Bipin Singh
Gender: male
Year Born: 1968
Chief Human Resources Officer
Manjul Tilak
Gender: male
Year Born:
Head of Investor Relations
Ravi Singh
Gender: male
Year Born:
Group President
Rupen Jhaveri
Gender: male
Year Born:
Managing Director of India Resurgence Asset Management Business Pvt. Ltd. (IndiaRF)
Shantanu Yeshwant Nalavadi
Gender: male
Year Born: 1971
Chief Executive Officer of Wholesale Lending-Piramal Enterprises Limited
Yesh Nadkarni
Gender: male
Year Born:
Chief Financial Officer
Upma Goel
Gender: female
Year Born: 1971
FAQs about Piramal Enterprises Limited
Who is the CEO of the company?
The CEO is Yesh Nadkarni.
What is the current market price of the stock?
The current price is ₹1,124.20.
What is the 52-week price range?
The range is ₹848.25-1355.3.
What is the market capitalization of the company?
The market capitalization is ₹25,485.63 crores.
What is the dividend yield?
The dividend yield is 0.98%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 43.81.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Piramal Enterprises Limited (ISIN: INE140A01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹25,485.63 crores and an average daily volume of 759,287 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹11.